Approvals· Brief · October 20, 2026, 4:02 PM ET

FDA approves once-weekly generic hormone therapy patch for women

The FDA approved the first generic of Climara Pro, a transdermal estradiol and levonorgestrel system (0.045 mg per day/0.015 mg) applied once a week for women with an intact uterus. The generic is therapeutically equivalent to Climara Pro and the most common adverse reactions are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome (≥5 %).

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation